Abstract

This grant is to provide statistical, computing and data management support for the Cancer and Acute Leukemia Group B (CALGB). These activities will involve collaboration in all appropriate activities associated with the planning, monitoring, data collection and analysis of data obtained from clinical trails conducted by the CALGB. Research and development of statistical methodology and computer software aimed at more effective planning, data management and analysis of clinical trials will also be conducted. The data base and computer science development will be the responsibility of Frontier Science and Technology Research Foundation under a consortium agreement with the Harvard School of Public Health.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA033601-12
Application #
3557313
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-12-01
Project End
1993-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost

  Institution

Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Baggstrom, Maria Q; Socinski, Mark A; Wang, Xiaofei F et al. (2017) Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol 12:843-849

Showing the most recent 10 out of 534 publications